produces clinical dextran by mixed-culture fermentation with Leuconostoc mesenteroides subsp. mesenteroides ATCC 10830
Biosafety Level
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
frozen
Storage Conditions
Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section
Type Strain
no
Disclosure
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC.
Preceptrol®
no
Medium
ATCC® Medium 28: Emmons' modification of Sabouraud's agar
Kim D, Day DF. A new process for the production of clinical dextran by mixed-culture fermentation of Lipomyces starkeyi and Leuconostoc mesenteroides. Enzyme Microb. Technol. 16: 844-848, 1994. PubMed: 7521648
Day DF, Kim D. Process for the production of dextran polymers of controlled molecular size and molecular size distributions. US Patent 5,229,277 dated Jul 20 1993
Kim D, Day DF. Isolation of a dextranase constitutive mutant of Lipomyces starkeyi and its use for the production of clinical size dextran. Lett. Appl. Microbiol. 20: 268-270, 1995. PubMed: 7766225
